Acetohexamide
An older oral diabetes medication belonging to the sulfonylurea class that stimulates the pancreas to release more insulin after meals. It was used to lower blood glucose in people with type 2 diabetes whose pancreas still produces some insulin. It has largely been replaced by newer sulfonylureas and other diabetes medications with more favorable safety profiles and less risk of prolonged low blood sugar.
الوزن الجزيئي
324,4000 g/mol
LogP
2,40
TPSA
101,00 Ų
قاعدة ليبينسكي للخمسة
ناجح
المجالات العلاجية
آلية العمل
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
InChI
InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)
Molecular Formula
C15H20N2O4S
HBD / HBA
2 / 4
الروابط القابلة للدوران
4
الذرات الثقيلة
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
An older oral diabetes medication belonging to the sulfonylurea class that stimulates the pancreas to release more insulin after meals. It was used to lower blood glucose in people with type 2 diabetes whose pancreas still produces some insulin. It has largely been replaced by newer sulfonylureas and other diabetes medications with more favorable safety profiles and less risk of prolonged low blood sugar.
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Yes, Acetohexamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1589. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 1989. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="acetohexamide"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/acetohexamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/acetohexamide/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/acetohexamide/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="acetohexamide"></drugfyi-drug>